AI assistant
Sending…
Denali Therapeutics Inc. — Director's Dealing 2018
Jun 26, 2018
31637_dirs_2018-06-26_4846e9e5-7a90-4458-9d92-bfe01a64800a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2018-06-22
Reporting Person: Schuth Alexander O. (COO and Secretary)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-06-22 | Common Stock | M | 5918 | $5.28 | Acquired | 5918 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-06-22 | Stock Option (right to buy) | $5.28 | M | 5918 | Disposed | 2027-03-07 | Common Stock (5918) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 685089 | Indirect |
Footnotes
F1: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee.
F2: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.
More from Denali Therapeutics Inc.
Regulatory Filings
2026
May 21
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 21
Regulatory Filings
2026
Apr 3
Regulatory Filings
2026
Mar 31
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 25
Annual Report
2026
Feb 26
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Jan 8